Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

10 Jan 2025

Abstract excerpt

ABSTRACT: Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide interpatient variability in treatment response, and the genetic basis of this variation remains largely unknown. Using a genome-wide CRISPR screen, we discovered that the loss of DNA nucleotidylexotransferase (DNTT) is a primary driver of InO...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39791601
DOI: 10.1182/blood.2024026085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaPMID 39791601Read ↗

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.Semantic proximity Read ↗

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicinSemantic proximity Read ↗

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.Semantic proximity Read ↗

DNTT activation, TdT-aided gene length mutation, and better prognosis in ATG-based regimen allo-HSCT in AML.Semantic proximity Read ↗

Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemiaSemantic proximity Read ↗

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLSemantic proximity Read ↗

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemiaSemantic proximity Read ↗

5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.Semantic proximity Read ↗

Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALLSemantic proximity Read ↗

Case Report: Immune-driven clonal selection underlying lineage switch from B-Precursor acute lymphoblastic leukemia to acute myeloid leukemia following inotuzumab ozogamicin.Semantic proximity Read ↗

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapySemantic proximity Read ↗

The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.